日本

The promise of Imaging Mass Cytometry

Gain unprecedented insights and answer important clinical research questions

Stratify

Stratifying subject populations is an important first step to improve clinical outcomes. However, complex single-cell phenotypes and the spatial heterogeneity of tissue architecture in the tumor microenvironment are not currently used to inform patient-specific health care decisions, nor is the frequently extensive variation between cohort subtype groups addressed. Cutting-edge high-multiplex imaging technologies are beginning to make significant contributions by generating comprehensive single-cell spatial data and enabling detailed analysis of cohort samples. Stratification based on unique features and cellular signatures associated with distinct clinical outcomes has been reported. Learn from these pioneering researchers who have utilized Imaging Mass Cytometry™ (IMC™) for subject stratification to answer clinical research questions and who propose its future use in precision medicine and clinical decision making.
Ask us about IMC
Stratify

First study to demonstrate the potential clinical value of highly multiplexed Imaging Mass Cytometry

Dr. Hartland Jackson Jana Fischer, MSc

Dr. Hartland Jackson
Investigator, Lunenfeld-Tanenbaum Research Institute Canada Research Chair in Systems Pathology

Jana Fischer, MSc
PhD student at University of Zurich

See an initial example of the use of high-dimensional data from IMC to assess novel breast cancer subtypes that are associated with clinical outcome in an early 2020 Jackson et. al Nature publication, “The single-cell pathology landscape of breast cancer.” Co-senior authors Hartland Jackson, PhD, and Jana Fischer, MSc, describe the analysis of the cellular composition and tissue organization that provided a view of intra-tumor phenotypic heterogeneity in a disease-relevant manner, with the potential to inform patient-specific diagnosis. This press release also describes how this retrospective clinical study used IMC to correlate novel cell signatures with distinct clinical outcomes.

» Read publication

» Read press release


Distinct combinations of cell phenotypes associated with genomic subtypes of breast cancer

IMC was coupled with multiplatform genomics to perform a systematic analysis of single-cell phenotypic and spatial correlates of genomic alterations in cancer. In “Imaging Mass Cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer,” a team of researchers investigated the structure of breast tumor ecosystems to better understand the phenotypic impact of genomic alterations. They identified characteristic tumor ecosystems that they believe can potentially be used to stratify patients and serve as targets for development of novel therapies in the future.

» Read publication


Identification of breast cancer tumors less likely to benefit from trastuzumab

Work guided by Rimm and Kluger at Yale School of Medicine resulted in a 2019 Clinical Cancer Research publication by Carvajal-Hausdorf et al. This research is one of the first examples of using IMC to assess structural and signaling proteins in a cohort of subjects treated with trastuzumab to discover associations with treatment benefits. In “Multiplexed (18-plex) measurement of signaling targets and cytotoxic T cells in trastuzumab-treated patients using Imaging Mass Cytometry,” the authors present evidence for the role of the immune system in trastuzumab mechanism of action, validate the IMC approach and demonstrate important translational relevance of results.

» Read publication

Contact us to ask about IMC

Contact us to get information about upcoming events, new products and more. You can also request a quote or ask to be contacted by your sales representative for a short discussion on how Imaging Mass Cytometry can help answer your challenging research questions.

Contact us now

For Research Use Only. Not for use in diagnostic procedures.